CY1124938T1 - Προφαρμακα υποκατεστημενων παραγωγων τριαζολης και χρησεις αυτων - Google Patents

Προφαρμακα υποκατεστημενων παραγωγων τριαζολης και χρησεις αυτων

Info

Publication number
CY1124938T1
CY1124938T1 CY20221100084T CY221100084T CY1124938T1 CY 1124938 T1 CY1124938 T1 CY 1124938T1 CY 20221100084 T CY20221100084 T CY 20221100084T CY 221100084 T CY221100084 T CY 221100084T CY 1124938 T1 CY1124938 T1 CY 1124938T1
Authority
CY
Cyprus
Prior art keywords
triazol
prodrugs
carboxamide
trifluoro
chlorophenyl
Prior art date
Application number
CY20221100084T
Other languages
English (en)
Inventor
Marie-Pierre COLLIN-KROEPELIN
Peter Kolkhof
Thomas Neubauer
Chantal Fuerstner
Elisabeth Pook
Matthias Beat WITTWER
Carsten Schmeck
Pierre Wasnaire
Heiko Schirmer
Hana CERNECKA
Karoline Droebner
Hanna Tinel
Anja Buchmueller
Thomas MONDRITZKI
Axel Kretschmer
Klemens Lustig
Robert Fricke
Guillaume Levilain
Ursula Krenz
Norbert Witowski
Original Assignee
Bayer Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Aktiengesellschaft filed Critical Bayer Aktiengesellschaft
Publication of CY1124938T1 publication Critical patent/CY1124938T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Η παρούσα εφεύρεση αναφέρεται σε προφάρμακα των 3-({3-(4-χλωροφαινυλ)-5-οξο-4-[(2S)-3,3,3-τριφθορο- 2-υδροξυπροπυλο]-4,5-διυδρο-1Η-1,2,4-τριαζολ-1-υλο Jμεθυλο)-1-[3-(τριφθορομεθυλο)-πυριδιν-2-υλο]-1Η-1,2,4-τριαζολο-5-καρβοξαμιδίου, 3-({3-(4-χλωροφαινυλ)-5-οξο-4-[(2S)-3,3,3-τριφθορο-2-υδροξυπροπυλο]-4,5-διυδρο-1Η-1,2,4-τριαζολ-1-υλο}μεθυλο)-1-[2-(τριφθορομεθυλο)-φαινυλο]-1Η-1,2,4-τριαζολο-5-καρβοξαμιδίου και 3-({3-(4-χλωροφαινυλ)-5-οξο-4-[(2S)-3,3,3-τριφθορο-2-υδροξυπροπυλο]-4,5-διυδρο-1Η-1,2,4-τριαζολ-1-υλο}μεθυλο)-1-(3-χλωροπυριδιν-2-υλο)-1Η-1,2,4-τριαζολο-5-καρβοξαμιδίου, σε διαδικασίες για την παρασκευή τέτοιων ενώσεων, σε φαρμακευτικές συνθέσεις που περιέχουν αυτές τις ενώσεις, και στη χρήση αυτών των ενώσεων ή συνθέσεων για τη θεραπευτική αντιμετώπιση και/ή πρόληψη παθήσεων, συγκεκριμένα για τη θεραπευτική αντιμετώπιση και/ή πρόληψη νεφρικών ή καρδιαγγειακών παθήσεων.
CY20221100084T 2017-10-24 2022-02-01 Προφαρμακα υποκατεστημενων παραγωγων τριαζολης και χρησεις αυτων CY1124938T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17197935 2017-10-24
PCT/EP2018/078364 WO2019081292A1 (en) 2017-10-24 2018-10-17 PRODRUGS OF SUBSTITUTED TRIAZOLE DERIVATIVES AND USES THEREOF

Publications (1)

Publication Number Publication Date
CY1124938T1 true CY1124938T1 (el) 2023-01-05

Family

ID=60162099

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20221100084T CY1124938T1 (el) 2017-10-24 2022-02-01 Προφαρμακα υποκατεστημενων παραγωγων τριαζολης και χρησεις αυτων

Country Status (38)

Country Link
US (1) US11298367B2 (el)
EP (1) EP3700913B1 (el)
JP (1) JP2021500365A (el)
KR (1) KR20200069361A (el)
CN (1) CN111225921A (el)
AR (1) AR113791A1 (el)
AU (1) AU2018356352A1 (el)
BR (1) BR112020007983A2 (el)
CA (1) CA3079767A1 (el)
CL (1) CL2020001076A1 (el)
CO (1) CO2020004945A2 (el)
CR (1) CR20200176A (el)
CU (1) CU24604B1 (el)
CY (1) CY1124938T1 (el)
DK (1) DK3700913T3 (el)
DO (1) DOP2020000076A (el)
EA (1) EA202091025A1 (el)
EC (1) ECSP20023056A (el)
ES (1) ES2906305T3 (el)
HR (1) HRP20220060T1 (el)
HU (1) HUE057278T2 (el)
IL (1) IL273949A (el)
JO (1) JOP20200099A1 (el)
LT (1) LT3700913T (el)
MA (1) MA50438B1 (el)
MX (1) MX2020004191A (el)
NI (1) NI202000030A (el)
PE (1) PE20210394A1 (el)
PH (1) PH12020550473A1 (el)
PL (1) PL3700913T3 (el)
PT (1) PT3700913T (el)
RS (1) RS62984B1 (el)
SG (1) SG11202003049WA (el)
SI (1) SI3700913T1 (el)
TW (1) TW201932117A (el)
UA (1) UA126456C2 (el)
UY (1) UY37948A (el)
WO (1) WO2019081292A1 (el)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021259852A1 (en) 2020-06-25 2021-12-30 Bayer Aktiengesellschaft Process for preparing 5-(alkoxycarbonyl)-and 5-(carboxamide)-1-aryl-1,2,4-triazole derivatives
WO2022112213A1 (en) 2020-11-30 2022-06-02 Bayer Aktiengesellschaft Crystalline forms of 3-[[3-(4-chlorophenyl)-5-oxo-4-((2s)-3,3,3-trifluoro- 2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]methyl]-1-[3- (trifluoromethyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3966781A (en) 1970-12-17 1976-06-29 Merck Sharp & Dohme (I.A.) Corporation Deuteration of functional group-containing hydrocarbons
DE19834047A1 (de) 1998-07-29 2000-02-03 Bayer Ag Substituierte Pyrazolderivate
DE19834044A1 (de) 1998-07-29 2000-02-03 Bayer Ag Neue substituierte Pyrazolderivate
DE19943635A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943639A1 (de) 1999-09-13 2001-03-15 Bayer Ag Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften
DE19943636A1 (de) 1999-09-13 2001-03-15 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE19943634A1 (de) 1999-09-13 2001-04-12 Bayer Ag Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften
AR031176A1 (es) 2000-11-22 2003-09-10 Bayer Ag Nuevos derivados de pirazolpiridina sustituidos con piridina
DE10110749A1 (de) 2001-03-07 2002-09-12 Bayer Ag Substituierte Aminodicarbonsäurederivate
DE10110750A1 (de) 2001-03-07 2002-09-12 Bayer Ag Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften
DE10220570A1 (de) 2002-05-08 2003-11-20 Bayer Ag Carbamat-substituierte Pyrazolopyridine
CA2551038C (en) 2003-12-22 2010-04-27 Pfizer Inc. Triazole derivatives as vasopressin antagonists
JP2007534740A (ja) 2004-04-28 2007-11-29 ファイザー・インク バソプレッシンＶ１ａ受容体の阻害剤としての３−ヘテロシクリル−４−フェニル−トリアゾール誘導体
EP2217591A4 (en) * 2007-11-06 2011-10-26 Astrazeneca Ab CERTAIN 2-PYRAZINONE DERIVATIVES AND THEIR USE AS NEUTROPHILES ELASTASE INHIBITORS
DE102010001064A1 (de) 2009-03-18 2010-09-23 Bayer Schering Pharma Aktiengesellschaft Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung
AR076542A1 (es) * 2009-05-22 2011-06-22 Merck Sharp & Dohme Antagonistas del receptor de orexina de isonicotinamida
LT2539326T (lt) 2010-02-27 2017-08-10 Bayer Intellectual Property Gmbh Sujungti bisariliniai ariltriazolonai ir jų panaudojimas
DE102010021637A1 (de) 2010-05-26 2011-12-01 Bayer Schering Pharma Aktiengesellschaft Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung
EP2682394A1 (de) 2010-07-09 2014-01-08 Bayer Intellectual Property GmbH 1H-Pyrazolo[3,4-b]pyridin-Triazine Verbindungen und ihre Verwendung zur Behandlung bzw. Prophylaxe von Herz-Kreislauf-Erkrankungen
DE102010040233A1 (de) 2010-09-03 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Bicyclische Aza-Heterocyclen und ihre Verwendung
DE102010043379A1 (de) 2010-11-04 2012-05-10 Bayer Schering Pharma Aktiengesellschaft Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung
WO2012112363A1 (en) 2011-02-14 2012-08-23 Merck Sharp & Dohme Corp. Cathepsin cysteine protease inhibitors
PT3057424T (pt) * 2013-10-16 2018-10-30 Bayer Cropscience Ag Combinações de compostos ativos que compreendem um derivado de (tio)carboxamida e um composto fungicida
KR20170081178A (ko) 2014-11-03 2017-07-11 바이엘 파마 악티엔게젤샤프트 히드록시알킬-치환된 페닐트리아졸 유도체 및 그의 용도
UY36571A (es) * 2015-03-05 2016-09-30 Bayer Cropscience Ag Combinaciones de compuestos activos
UY37221A (es) 2016-05-03 2017-11-30 Bayer Pharma AG Derivados de feniltriazol sustituidos con amida y usos de estos
US9988367B2 (en) 2016-05-03 2018-06-05 Bayer Pharma Aktiengesellschaft Amide-substituted pyridinyltriazole derivatives and uses thereof
US10525041B2 (en) 2016-05-03 2020-01-07 Bayer Pharma Aktiengesellschaft Fluoroalkyl-substituted aryltriazole derivatives and uses thereof
WO2017191115A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Oxoalkyl-substituted phenyltriazole derivatives and uses thereof
WO2017191114A1 (en) 2016-05-03 2017-11-09 Bayer Aktiengesellschaft Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof
WO2017191105A1 (en) 2016-05-03 2017-11-09 Bayer Pharma Aktiengesellschaft Amide-substituted aryltriazole derivatives and uses thereof
US10927098B2 (en) 2016-10-20 2021-02-23 Bayer Pharma Aktiengesellschaft Hydroxyalkyl-substituted triazole derivatives and uses thereof

Also Published As

Publication number Publication date
LT3700913T (lt) 2022-01-25
AR113791A1 (es) 2020-06-10
WO2019081292A1 (en) 2019-05-02
SI3700913T1 (sl) 2022-02-28
TW201932117A (zh) 2019-08-16
AU2018356352A1 (en) 2020-04-16
US11298367B2 (en) 2022-04-12
DK3700913T3 (da) 2022-02-07
CA3079767A1 (en) 2019-05-02
PE20210394A1 (es) 2021-03-02
NI202000030A (es) 2020-10-09
KR20200069361A (ko) 2020-06-16
DOP2020000076A (es) 2020-08-31
BR112020007983A2 (pt) 2020-10-27
PL3700913T3 (pl) 2022-02-21
CU20200040A7 (es) 2021-03-11
ECSP20023056A (es) 2020-12-31
PH12020550473A1 (en) 2021-03-08
ES2906305T3 (es) 2022-04-18
IL273949A (en) 2020-05-31
UY37948A (es) 2019-05-31
US20200338096A1 (en) 2020-10-29
MX2020004191A (es) 2020-08-03
JP2021500365A (ja) 2021-01-07
SG11202003049WA (en) 2020-04-29
EP3700913B1 (en) 2021-11-10
CU24604B1 (es) 2022-06-06
MA50438B1 (fr) 2022-03-31
PT3700913T (pt) 2022-01-31
EP3700913A1 (en) 2020-09-02
UA126456C2 (uk) 2022-10-05
CL2020001076A1 (es) 2021-02-19
EA202091025A1 (ru) 2020-07-30
JOP20200099A1 (ar) 2020-05-06
HUE057278T2 (hu) 2022-04-28
CO2020004945A2 (es) 2020-05-05
CN111225921A (zh) 2020-06-02
CR20200176A (es) 2020-07-24
RS62984B1 (sr) 2022-03-31
MA50438A (fr) 2020-09-02
HRP20220060T1 (hr) 2022-04-15

Similar Documents

Publication Publication Date Title
CY1124084T1 (el) Αμιδο-υποκατεστημενα παραγωγα πυριδινυλοτριαζολης και χρησεις αυτων
CY1124938T1 (el) Προφαρμακα υποκατεστημενων παραγωγων τριαζολης και χρησεις αυτων
PH12020500091A1 (en) Combination comprising palbociclib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7] annulene-2-carboxylic acid and its use for the treatment of cancer
RS53716B1 (en) COMBINED CANCER THERAPY WITH HSP90 INHIBITORS
HUP9901550A2 (hu) Növényimmunizáló hatású benzotiadiazolszármazékot tartalmazó szinergetikus fungicid készítmények és alkalmazásuk
AR102987A1 (es) Combinaciones de compuestos activos que comprenden un derivado de (tio)carboxamida y compuesto(s) fungicida(s)
BR112017009282A2 (pt) misturas fungicidas, composição pesticida, métodos para controlar pragas fitopatogênicas, para melhorar a fitossanidade e para proteção de material de propagação de plantas contra pragas, e, material de propagação de plantas.
PE20210859A1 (es) Inhibidores de triazol glicolato oxidasa
CL2018003107A1 (es) Procedimiento para la preparación de derivados de 1-fenilo-1,2,4-triazol sustituidos por 5-hidroxialquilo
EA202091423A1 (ru) Сокристаллы боскалида и триазолов
MX2019014836A (es) Formulaciones estabilizadas que contienen protioconazol con bajo contenido de 2-(1-clorociclopropanil)-1-(2-clorofenil)-3-(1h-1,2,4 -triazol-1-il)propan-2-ol.
UY36964A (es) Combinaciones de principios activos que comprenden un derivado de (tio) carboxamida y un compuesto funguicida
JP2016525113A5 (el)
JP2016520636A5 (el)
AR035220A1 (es) Mezclas fungicidas.
EP3233079A4 (en) (s)-n-(3-(6-isopropoxypyridin-3-yl)-1h-indazol-5-yl)-1-(2-(4-(4-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)-3,6-dihydropyridin-1(2h)-yl)-2-oxoethyl)-3-(methylthio)pyrrolidine-3-carboxamide compositions for pharmaceutical preparations
AR102155A1 (es) Derivados de triazol fungicidas
AR111255A1 (es) Derivados de 4-piperidin-n-(pirimidin-4-il)croman-7-sulfonamidas inhibidores de canales de sodio
TH93936B (th) สารประกอบต่าง ๆ
TH167726B (th) สารยับยั้ง glyt1 สำหรับการใช้ในการรักษาความผิดปกติทางโลหิตวิทยา
TH115254B (th) สารประกอบไวนิลอินดาโซลอิล
TH93936A (th) สารประกอบต่าง ๆ